Phase 1 Hidradenitis Suppurativa Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Hidradenitis SuppurativaPsoriatic ArthritisAxial Spondyloarthritis+1 more
UCB Biopharma SRL20 enrolled12 locationsNCT06888193
Recruiting
Phase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Incyte Corporation24 enrolled24 locationsNCT07049575
Not Yet Recruiting
Phase 1
A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of subcutaneous NAV-242 in adults with Hidradenitis Suppurativa.
Hidradenitis Suppurativa
Navigator Medicines6 enrolled1 locationACTRN12626000154303
Recruiting
Phase 1Phase 2
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Hidradenitis Suppurativa
Shanghai Huaota Biopharmaceutical Co., Ltd.15 enrolled1 locationNCT06895499
Recruiting
Phase 1
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
Hidradenitis Suppurativa (HS)
Wynn Medical Center30 enrolled1 locationNCT07155239
Recruiting
Phase 1
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
Atopic DermatitisRheumatoid Arthritis (RA)Hidradenitis Suppurativa (HS)
Shanghai Qilu Pharmaceutical Research and Development Center LTD102 enrolled1 locationNCT06946641
Recruiting
Phase 1
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
Healthy VolunteerAtopic DermatitisHidradenitis Suppurativa
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.127 enrolled1 locationNCT06082323